Novartis AG (0QLR.IL)
IOB · CHF · Healthcare · Drug Manufacturers - General
CHF 128.38 (+0.79%) as of
Key statistics
- Market cap
- 294.36B
- P/E (TTM)
- 39.99
- EPS (TTM)
- 3.21
- Dividend yield
- 3.78%
- 52-week range
- 97.10 – 132.64
- Beta
- 0.49
- Revenue (TTM)
- 53.07B
- Profit margin
- 14.41%
- Volume
- 485.23k
About Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Headquarters
- Basel, Switzerland
- Employees
- 103,000
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.